Emmecell, a clinical-stage biotechnology company developing magnetic cell delivery technologies for ophthalmic diseases, announced the successful closing of a strategic financing round. The financing included participation from existing investors as well as strategic industry participant Bausch + Lomb.
The proceeds from the financing will support the advancement of Emmecell’s clinical programs, expansion of operational capabilities, and continued development of its proprietary magnetic cell delivery platform.
Corneal endothelial disease, including Fuchs’ dystrophy and endothelial cell loss caused by trauma or surgery, affects millions of people worldwide and remains a major cause of vision impairment. Although corneal transplantation is currently the standard treatment for advanced disease, reliance on donor tissue availability and the risks associated with surgery underscore the need for alternative therapies.
Emmecell’s platform is designed to address one of the key challenges in cell therapy delivery by precisely guiding therapeutic cells to diseased ocular tissues. The technology aims to improve cell localization, retention, and engraftment, enabling controlled positioning of therapeutic cells within the eye and supporting the development of minimally invasive regenerative therapies.
Headquartered in Menlo Park, California, Emmecell is developing treatments for corneal disease, geographic atrophy, and other ophthalmic conditions. Its technology platform is intended to provide targeted cell delivery as an alternative to traditional surgical and pharmacological approaches.
KEY QUOTES:
“This financing marks an important milestone for Emmecell as we continue advancing our magnetic cell delivery platform and clinical programs. We are grateful for the support of both new and existing investors as we work to develop innovative treatment options for patients with serious ophthalmic diseases.”
Ramin Valian, Chief Executive Officer of Emmecell
“Emmecell’s magnetic cell delivery technology represents an innovative approach to treating corneal endothelial disease. The ability to precisely position therapeutic cells has the potential to advance treatment options for patients while addressing an important unmet need in ophthalmology.”
Sam Garg, MD, Vice Chair of Clinical Ophthalmology and Medical Director of the Gavin Herbert Eye Institute, and Chair of Emmecell’s Medical Advisory Board
